Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands.
Radiother Oncol. 2012 May;103(2):183-7. doi: 10.1016/j.radonc.2011.12.014. Epub 2012 Jan 24.
It has been shown that seroma volumes decrease during breast conserving radiotherapy in a significant percentage of patients. We report on our experience with an adaptive radiation therapy (ART) strategy involving rescanning and replanning patients to take this reduction into account during a course of intensity-modulated radiation therapy with simultaneously integrated boost (IMRT-SIB).
From April 2007 till December 2009, 1274 patients eligible for SIB treatment were enrolled into this protocol. Patients for which the time between the initial planning CT (CT(1)) and lumpectomy was less than 30 days and who had an initial seroma volume >30 cm(3) were rescanned at day 10 of treatment (CT(2)) and replanned when significant changes were observed by the radiation oncologist. Patients received 28 fractions of 1.81 Gy to the breast and 2.30 Gy to the boost volume.
Nine percent (n=113) of the 1274 patients enrolled met the criteria and were rescanned. Of this group, 77% (n=87) of treatment plans were adapted. Time between surgery and CT(1) (20 days versus 20 days for adapted and non-adapted plans, p=0.89) and time between CT(1) and CT(2) (21 days versus 22 days for adapted and non-adapted plans, p=0.43) revealed no procedural differences which might have biased our results. In the adapted plans, seroma decreased significantly from 60 to 27 cm(3) (p<0.001), TBV from 70 to 45 cm(3) (p<0.001) and PTV(boost) from 277 to 220 cm(3) (p<0.001). The volume receiving more than 95% of the boost dose (V(95%(total-dose))) could be reduced by 19% (linear fit, R(2)=0.73) from on average 360 to 292 cm(3) (p<0.001). Delay in treatment and the use of a prolonged treatment schedule with different fractionation for patients with seroma could thus be prevented.
The adaptive radiation therapy IMRT-SIB procedure has proven to be efficient and effective, leading to a clinically significant reduction of the high dose volume. Seroma present in a subgroup of patients referred for breast radiation therapy does not hamper the introduction of highly conformal IMRT-SIB techniques.
研究表明,在接受保乳放疗的患者中,有很大一部分患者的血清肿体积会减少。我们报告了一种自适应放疗(ART)策略的经验,该策略涉及重新扫描和重新规划患者,以便在调强放疗同时整合推量(IMRT-SIB)过程中考虑到这种减少。
从 2007 年 4 月至 2009 年 12 月,共有 1274 名符合 SIB 治疗条件的患者入组该方案。对于初始计划 CT(CT(1))和乳房切除术之间的时间少于 30 天且初始血清肿体积>30cm3的患者,在治疗第 10 天(CT(2))进行重新扫描,并由放射肿瘤学家观察到明显变化时进行重新计划。患者接受 28 次 1.81Gy 的乳房照射和 2.30Gy 的推量体积照射。
1274 名入组患者中有 9%(n=113)符合标准并进行了重新扫描。在这组患者中,77%(n=87)的治疗计划进行了调整。手术和 CT(1)之间的时间(20 天与适应和不适应计划的 20 天,p=0.89)以及 CT(1)和 CT(2)之间的时间(适应和不适应计划的 21 天与 22 天,p=0.43)没有显示出可能影响我们结果的程序差异。在适应计划中,血清肿从 60 减少到 27cm3(p<0.001),TBV 从 70 减少到 45cm3(p<0.001),PTV(推量)从 277 减少到 220cm3(p<0.001)。接受 95%以上推量剂量的体积(V(95%(总剂量)))可以从平均 360 减少到 292cm3(p<0.001),减少 19%(线性拟合,R2=0.73)。因此,可以防止由于血清肿而导致的治疗延迟和对接受放疗的患者使用不同分割方案的延长治疗时间。
自适应放疗 IMRT-SIB 程序已被证明是有效和有效的,可导致高剂量体积的临床显著减少。在接受乳房放疗的患者亚组中存在的血清肿不会阻碍高度适形 IMRT-SIB 技术的引入。